Koru Medical Systems, Inc. · NASDAQ:KRMD
Koru Medical Systems — Q2 2026 Earnings Presentation
17 slides from Koru Medical Systems's earnings presentation, Aug 5, 2026
Slide 1: KORU Medical Systems Q2 2026 Earnings Call
KORU Medical Systems Q2 2026 Earnings Call August 5, 2026 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements. Forward-looking statements dis
Slide 3: Global Leader in Large-Volume Subcutaneous Drug Delivery
Q2 2026 Results Global Leader in Large-Volume Subcutaneous Drug Delivery Easy to Use, Differentiated Infusion Devices Capitalizing on the ongoing shift from IV hospital settings to subcutaneous therapy in the home and in infusion clinics KORU Freedom Infusion System is, today, primarily used by ~60,
Slide 4: Second Quarter Performance Highlights
Q2 2026 Results Second Quarter Performance Highlights Revenue: $12M Gross Margin: 65.1% Net Income: $0.3M 18% growth over Raising FY guidance from 222% improvement over prior year period 61-63% to 62-64% prior year period 4
Slide 5: Strategic Vision Intact: Progress Across Growth Pillars
Q2 2026 Results Strategic Vision Intact: Progress Across Growth Pillars KORU’s Strategic Growth Pillars Protect and Grow our Enable More Drugs, 1 2 Expand Internationally 3 Core Domestic Business Reach More Patients • 12% y/y growth • 59% y/y growth • 8 non-Ig drugs in pipeline • SCIg recurring reve
Slide 6: Strategic Updates
Q2 2026 Results Strategic Updates Connected Monitoring Technology Acquisition Real-time data insights for pharma and specialty pharmacy partners Deferoxamine 510(k) 510(k) submitted at end of Q1 and navigating standard FDA review process; Estimated 200,000 annual infusions1 Secondary Immunodeficienc
Slide 7: Q2 Y/Y Revenue by Business: $12M+, 18% Growth
Q2 2026 Results Q2 Y/Y Revenue by Business: $12M+, 18% Growth Net Revenues; In Millions Domestic Core • Increased 12% y/y $12.0 • Outpaced SCIg market growth $0.6 • Driven by new patient starts and market share gains 18% $10.2 • Growth across all product lines $0.9 $3.5 International Core $2.2 • Inc
Slide 8: Gross Margin Guidance Raised On Continued Strength
Q2 2026 Results Gross Margin Guidance Raised On Continued Strength Consistent Performance >60% Gross Margin • 160 basis point increase y/y 65.1% • Lower manufacturing costs 63.5% resulting from production 62 - 64% through-put efficiencies 62.3% 61 - 63% • Higher average selling prices driven by pric
Slide 9: Cash Usage of ($0.5M): Positive CF from Operations
Q2 2026 Results Cash Usage of ($0.5M): Positive CF from Operations Cash Balance as of June 30, 2026: $8.3M Key Drivers • 2Q26 cash usage of $0.5M $8.8M • Positive cash flow from $2.0M $8.3M operations as net losses continue to decline ($0.6M) ($1.1M) • Investing activities included purchase of techn
Slide 10: 1H 2026 Financial Highlights: Continued Demonstration of Operating Leverage
Q2 2026 Results 1H 2026 Financial Highlights: Continued Demonstration of Operating Leverage and Disciplined Financial Profile 1H 2026 1H 2025 Y/Y Δ Revenue $23.8M $19.8M +20% Growth Gross Margin 63.3% 63.1% +20bps OpEx $15.3M $14.1M +9% Increase Net Loss ($0.6M) ($1.4M) 60% Improvement Adj. EBITDA*
Slide 11: 2026 Outlook
2026 Outlook Adjusting 2026 Guidance Revenue Gross Margin Profitability Growth Profile Metrics Positive Adj. EBITDA & $47.5-$48.5M, 62-64% Year End Cash Balance 15-18% growth vs. prior range of 61-63% > $7.5M Key Drivers/Milestones Key Drivers/Milestones Key Drivers/Milestones • Continued U.S. and •
Slide 12: Strategically Positioned for Accelerated Growth
2026 Outlook Strategically Positioned for Accelerated Long Term Growth Financial Goals3 Recent Accomplishments1 $100M revenue Strong Fundamentals, Significant Opportunity1 18% 2Q26 revenue Large and growing market growth over prior year Accelerated for SC drug delivery; ~95 period double-digit >10mL
Slide 13: Consistent Execution and Key Strategic Progress
Q2 2026 Results Consistent Execution and Key Strategic Progress 1 Q2 revenue of $12M represents growth of 18% over the prior year period 2 Net income improvement of 222% over the prior year period Acquired a connected monitoring digital asset to potentially strengthen patient support infrastructure
Slide 14: Appendix
Appendix 14
Slide 15: Execution Milestones on Path to Accelerated Revenue Growth
2026 Outlook Execution Milestones on Path to Accelerated Revenue Growth Adjusting 2026 Financial Guidance • 15-18% revenue growth • Positive Adjusted EBITDA, Cash of >$7.5M • Gross margin 62-64% Enable More Drugs, Reach More Patients • Add 4 new pipeline collaborations for FY26: 2 of 4 complete • De
Slide 16: Pipeline Opportunities in SCIg and New Drug Therapies
Enabling New Drugs Pipeline Opportunities in SCIg and New Drug Therapies 8 in Pipeline 9 on Label Active Opportunities for New Drugs and Indications1 Drugs on KORU’s Freedom Infusion System’s Label Commercial Annual Global SCIg 5.4M3 Annual Infusions Drug Asset Infusions Estimate3 Estimated Deferoxa
Slide 17: Non-GAAP Financial Measures
Non-GAAP Financial Measures This presentation includes the non-GAAP financial measures “adjusted EPS”, "adjusted diluted EPS“, and “adjusted EBITDA” that are not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used by othe